Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics reported Q3 2026 financials, with $59M in cash. The FDA accepted its NDA resubmission for oxylanthanum carbonate (OLC), setting a PDUFA date of March 25, 2027. The company expects runway beyond 2027, including potential OLC launch costs.

Original reporting
Published Nov 16, 2026, 7:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 7:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update — source image
Decision brief

The 30-second read

$UNCYNeutralMed
01

Why it matters

The FDA acceptance is a material regulatory milestone; the financials show a modest loss but ample cash runway, setting the stage for a potential launch if approved.

02

Market read

The news provides a fresh regulatory milestone and earnings data for a micro‑cap biotech, offering a basis for short‑term positioning ahead of the PDUFA decision.

03

What to watch

Potential pre‑approval inspection of the new manufacturing vendor could delay the timeline.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

Unicycive Therapeutics is a Nasdaq‑listed biotech focused on kidney disease treatments, reporting its Q3 2026 results and regulatory update.

Company-level read

Ticker impact

$UNCYNeutralHigh confidence
Context

The company announced FDA acceptance of its NDA resubmission for oxylanthanum carbonate with a PDUFA target date of March 25, 2027 and released its Q3 2026 financial results.

Expected impact

potential modest upside as investors price in the chance of approval, but limited upside until FDA decision.

Evidence & confidence

Regulatory progress is a key catalyst for biotech stocks; the cash position supports continued development, but no immediate revenue.

Market effects

Positive signal for the kidney‑disease therapeutic sector as FDA acceptance may encourage peer pipelines.

Limited to US biotech investors; no broader regional effect.

Minimal global impact beyond niche biotech community.

Counterpoint

The NDA acceptance may not translate into approval; investors could remain cautious given the pending review.

Key entities

  • Unicycive Therapeutics, Inc.

    Nasdaq‑listed biotech developing oxylanthanum carbonate for hyperphosphatemia.

  • FDA

    U.S. Food and Drug Administration, accepted the NDA resubmission.

Related articles

$UNCYMed

Unicycive Therapeutics Reports Q3 2026 Results, $59 Million in Cash and Securities

Unicycive Therapeutics reported a Q3 2026 net loss of $7.0 million, or $0.25 per share, with $59 million in cash. The FDA accepted its OLC NDA resubmission, setting a March 25, 2027 PDUFA date. The company expects its cash runway to extend beyond 2027, including potential OLC launch costs. Research and development expenses decreased to $2.2 million from $3.0 million a year earlier, while general and administrative expenses increased to $6.6 million from $4.4 million.

$UNCYMed

Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update - New Drug Application (NDA) for oxylanthanum carbonate (OLC) accepted by the U.S. Food and Drug Administration (FDA), with an assigned Prescription Drug User Fee Act (

MedAI 8/10

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA

Unicycive Therapeutics announced the FDA accepted its resubmitted NDA for Oxylanthanum Carbonate (OLC), setting a PDUFA target action date of March 25, 2027. The resubmission addresses manufacturing deficiencies cited in a prior CRL. OLC is an investigational phosphate binder for CKD patients on dialysis, with potential market advantages due to its formulation.

$UNCYMed

FDA accepts Unicycive resubmission for kidney drug application

Unicycive Therapeutics (UNCY) announced the FDA accepted its resubmitted New Drug Application for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients. The FDA set a target action date of March 25, 2027. The resubmission includes new manufacturing data from a different vendor, following a Complete Response Letter in June 2026. The company hopes for potential approval and does not know if the FDA will conduct a pre-approval inspection.